Who is sponsoring NCT05126290?

NCT05126290 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT05126290?

Interventions in NCT05126290: Collection of personal and family history from CAFÉ Study participants.

What condition does NCT05126290 study?

NCT05126290 studies Cancer Gene Mutation, Gastric Cancer, Breast Cancer.

Is NCT05126290 still recruiting?

NCT05126290 is currently recruiting now. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT05126290: CAFÉ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CTNNA1 Familial Expansion Study

Recruiting now Last updated 5 February 2026

What this trial tests

trial testing Collection of personal and family history from CAFÉ Study participants in Cancer Gene Mutation in 100 participants. Currently enrolling.

Timeline

16 March 2021

Primary endpoint
1 January 2028

1 January 2028

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	16 March 2021
Primary completion	1 January 2028
Estimated completion	1 January 2028
Sites	1 location across United States

Drugs / interventions tested

Collection of personal and family history from CAFÉ Study participants

Conditions studied

Cancer Gene Mutation — all drugs for Cancer Gene Mutation →
Gastric Cancer — all drugs for Gastric Cancer →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Cancer Gene Mutation or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Young-Onset Gastric Cancer: Clinical and Genetic Perspectives.
Michelon I, Saeed A. · · 2026 · PMID 41517847 · DOI 10.5230/jgc.2026.26.e9

Verify or expand the search:

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05126290 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05126290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing